A report commissioned by the European pharmaceutical industry federation, EFPIA, has pointed to significant gaps in understanding the broader public health impact of various clinical trial data disclosure activities.
Despite increasing volumes of data being made public in response to the ever evolving mandatory and voluntary clinical trial disclosure landscape, the true benefits of these activities on public health remain unclear and insufficiently measured, states the